RxDoctor Payments DataLook up a doctor →

Christopher Naquin, MD

Family Medicine · Kenner, LANPI 1760489579

Payments from drug & device makers

$18,798in general payments, 2019–2025

Across 1,114 payments — averaging $16.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$3K
  • AstraZeneca$2K
  • Pfizer$2K
  • Novo Nordisk$2K
  • AbbVie$1K
  • Boehringer Ingelheim$1K
  • plus $6K from 34 others

What the payments were for

  • Food & beverage$18,68499%
  • Education$1141%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$18,798 in reported general payments places this provider in the 95th percentile of 1,469 family medicine providers in Louisiana.

See all family medicine providers in Louisiana

Medicare billing

Part B allowed, 2024
$53,702
Medicare patients
74
Services billed
848

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide136$159,049
Trelegy ElliptaFluticasone/Umeclidin/Vilanter186$135,239
JardianceEmpagliflozin155$122,196
EliquisApixaban131$118,775
RybelsusSemaglutide42$60,912
FarxigaDapagliflozin Propanediol69$57,283
MounjaroTirzepatide34$43,825
MyrbetriqMirabegron45$24,499
XareltoRivaroxaban25$23,266
TrulicityDulaglutide19$17,071
Breztri AerosphereBudesonide/Glycopyr/Formoterol19$14,601
JanuviaSitagliptin Phosphate18$14,097
ShingrixVaricella-Zoster Ge/As01b/Pf58$12,997
Tresiba Flextouch U-200Insulin Degludec20$11,902
TradjentaLinagliptin20$9,365

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$2,185$219,960178 claims
GSKTrelegy Ellipta, Shingrix, Breo Ellipta, Anoro Ellipta$2,682$164,743281 claims
Boehringer IngelheimJardiance, Tradjenta, Spiriva Respimat$1,338$137,157186 claims
PfizerEliquis$2,240$118,775131 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$2,484$79,197111 claims
Lilly USA, LLCMounjaro, Trulicity$1,232$60,89653 claims
Astellas Pharma US IncMyrbetriq$380$24,49945 claims
Johnson & JohnsonXarelto$221$23,26625 claims
MerckJanuvia$404$14,09718 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,469 family medicine providers in Louisiana.

Other family medicine in Kenner

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →